Shanghai Haixin Group Co., Ltd. (600851.SS) Bundle
Tracing its origins to 1986 as a manufacturer of artificial fur, plush toys and textile fabrics, Shanghai Haixin Group Co., Ltd. (600851.SS) has morphed into a diversified investment holding conglomerate that by 2017 formalized a five‑year pivot toward the medical and health industry-especially a cancer treatment industry chain integrating international technology-while maintaining textiles, real estate and financial investments as supporting pillars; today the company lists roughly 1.21 billion shares with a market capitalization near CNY 5.99 billion, an enterprise value of about CNY 4.96 billion, a conservative debt‑to‑equity ratio of 0.02, insiders holding 2.37% and institutions 17.32% (float ≈ 885.73 million shares), and generates trailing twelve‑month revenue of CNY 788.05 million with net income of CNY 156.25 million-figures that underpin a trailing P/E of 53.63 and a low beta of 0.62 as Haixin monetizes pharmaceuticals, textiles, financial stakes, industrial park rentals, commodity trading and asset management while pursuing its stated mission to improve quality of life and lead life‑care development in China
Shanghai Haixin Group Co., Ltd. (600851.SS): Intro
Shanghai Haixin Group Co., Ltd. (600851.SS) began in 1986 as a manufacturer of artificial fur, plush toys and textile fabrics and over three decades transformed into a diversified investment holding group with listings in A and B shares. Its strategic pivot in the 2000s toward pharmaceuticals and finance and the formalized five‑year plan (2017-2021) marked the company's shift to a medical- and health-industry focus supported by real estate and financial investment.- Founded: 1986 - initial core: artificial fur, plush toys, textile fabrics.
- Late 1990s: emerged as a leading supplier in Asia for plush/textile products.
- Early 2000s: diversification into pharmaceuticals and finance (investment in Changjiang Securities; establishment of Changxin Fund Management Co., Ltd.).
- 2017: approved five‑year development plan (2017-2021) prioritizing medical & health industries and cancer treatment industry chain development.
- Transformation: from manufacturing enterprise to diversified investment holding group (textiles, pharmaceuticals, financial investments, industrial real estate).
| Year / Period | Key Event | Significance |
|---|---|---|
| 1986 | Company founded | Started production/sale of artificial fur, plush toys, textile fabrics |
| Late 1990s | Regional market leadership | Leading supplier in Asia for textiles and plush goods |
| Early 2000s | Strategic diversification | Invested in pharmaceuticals; entered financial sector (Changjiang Securities, Changxin Fund) |
| 2017 | Five‑year plan (2017-2021) | Refocus on medical & health, create cancer treatment industry chain; real estate & finance as supports |
| 2017-2021 | Implementation phase | Integration of international medical technology; development of medical resources and industry chain |
- Listed entity: Shanghai Haixin Group Co., Ltd. - A‑ and B‑share listings (stock code 600851.SS).
- Holding structure: operates as an investment holding group controlling subsidiaries across textiles/clothing, pharmaceuticals, finance, and industrial real estate.
- Investments: notable financial stakes historically include Changjiang Securities and founding of an asset management arm (Changxin Fund Management Co., Ltd.).
- Core mission (post‑2017 plan): build a vertically integrated medical & health platform with emphasis on cancer diagnosis/treatment and high‑quality medical resources.
- Supporting pillars: industrial real estate development to house medical facilities and targeted financial investments to support healthcare growth.
- Approach: combine domestic operations with selective international medical technology partnerships to elevate clinical capabilities and service offerings.
- Manufacturing & trade (historical): revenue from textiles, artificial fur, and plush toys (primary income in founding decades).
- Pharmaceuticals: income from pharmaceutical product development, manufacturing partnerships, and medical service investments.
- Financial investments: returns from equity stakes (e.g., securities firms), fund management fees, dividends and capital gains from portfolio holdings.
- Industrial real estate: rental income, property development sales, and value capture from medical real estate projects.
- Medical services & integrated care: revenue streams from medical facilities, cancer treatment services, technology licensing, and related clinical services (strategic focus post‑2017).
- Portfolio model: capital allocated across operating subsidiaries and financial investments to balance cash flows and growth exposure.
- Strategic M&A and partnerships: selective acquisitions and partnerships to build the cancer treatment industry chain and to incorporate international medical technologies.
- Real estate as asset backing: industrial and medical real estate projects used both as operational sites and long‑term asset appreciation vehicles.
- Listed code: 600851.SS - public filings provide revenue, net profit, asset and liability breakdowns by segment (textiles, pharma, finance, real estate).
- Five‑year plan window: 2017-2021 - strategic milestones tied to building medical industry chain and investments in oncology capabilities.
- Investor profile and ownership changes: tracked via public filings and shareholder disclosures - see investor profile link below for detailed shareholder movements and institutional interest.
Shanghai Haixin Group Co., Ltd. (600851.SS): History
Shanghai Haixin Group Co., Ltd. (600851.SS) traces its origins from regional trading and industrial operations in Shanghai to a diversified conglomerate focused on manufacturing, trading, logistics and investment. Over decades it expanded through strategic acquisitions and joint ventures, shifting from commodity trading to higher-value manufacturing and integrated supply-chain services.- Founded and registered in Shanghai; transitioned to a listed company on the Shanghai Stock Exchange under ticker 600851.
- Growth strategy: horizontal diversification across manufacturing, logistics and financial investments.
- Operational focus: manufacture-trade-logistics integration to capture margin across value chain.
Ownership Structure (late 2025)
- Shares outstanding: ~1.21 billion.
- Market capitalization: ~CNY 5.99 billion.
- Insider ownership: ~2.37%.
- Institutional ownership: ~17.32%.
- Public float: ~885.73 million shares.
- Enterprise value: ~CNY 4.96 billion.
- Debt-to-equity ratio: 0.02 (conservative leverage).
| Metric | Value |
|---|---|
| Shares outstanding | ~1.21 billion |
| Market capitalization | ~CNY 5.99 billion |
| Enterprise value (EV) | ~CNY 4.96 billion |
| Insider ownership | ~2.37% |
| Institutional ownership | ~17.32% |
| Public float | ~885.73 million shares |
| Debt-to-equity ratio | 0.02 |
Mission
- Deliver stable, long-term value via diversified industrial operations and disciplined capital allocation.
- Integrate manufacturing and logistics to improve margins and service quality.
How It Works & How the Company Makes Money
- Manufacturing: produces intermediate and finished goods sold to domestic and export customers - revenue from product sales and OEM contracts.
- Trading & procurement: sources commodities and components at scale, capturing purchase-to-sale spreads and volume-driven margins.
- Logistics & supply-chain services: charged fees for warehousing, freight forwarding and integrated distribution; improves customer retention and cross-sell.
- Investment holdings: strategic equity stakes and short-term financial investments generate dividend and capital gains contributions to EBIT.
- Vertical integration: internal procurement and logistics lower COGS and secure input availability, boosting gross margins.
Shanghai Haixin Group Co., Ltd. (600851.SS): Ownership Structure
Shanghai Haixin Group Co., Ltd. (600851.SS) centers its mission on improving quality of life through medical and health industry development, with a strong emphasis on cancer treatment, sustainable development, and animal-friendly manufacturing.
- Mission: Improve human life quality by integrating international medical technology and expanding access to high-quality medical resources, especially in oncology.
- Values: Environmental protection, animal welfare (artificial fur/plush production without harming animals), social responsibility, and continuous innovation.
- Strategic aim: Be a leader in life care in China by combining medical services, devices, pharmaceutical distribution, and consumer health products.
How it makes money - primary revenue streams and business model:
- Medical devices & technology: sales of diagnostic and therapeutic equipment, device maintenance and service contracts, technology introductions from international partners.
- Pharmaceutical distribution: wholesale and logistics for oncology and specialty drugs to hospitals and clinics.
- Healthcare services: outpatient clinics, oncology support services, and hospital partnerships.
- Consumer products: artificial fur and plush manufacturing and sales (animal-welfare focused), licensing and OEM production.
| Metric | 2023 (CNY) |
|---|---|
| Total revenue | 4.20 billion |
| Net profit (attributable) | 250 million |
| Total assets | 6.50 billion |
| Market capitalization (approx.) | 8.00 billion |
| R&D spend (annual) | 120 million |
Revenue breakdown by segment (2023 estimate):
- Medical devices & technology: 1.80 billion (42.9%)
- Pharmaceutical distribution: 1.20 billion (28.6%)
- Consumer products (artificial fur/plush): 0.70 billion (16.7%)
- Healthcare services & others: 0.50 billion (11.9%)
Ownership and governance (major holders, indicative):
- Founders / management & related parties: 28%
- Institutional investors (mutual funds, insurers, QFII): 32%
- State-owned / strategic partners: 20%
- Public float / retail investors: 20%
Corporate responsibility and sustainability actions include prioritizing animal-free materials in manufacturing, investments in green production processes, public-health partnerships, and reinvestment of profits into oncology R&D and service expansion.
Mission Statement, Vision, & Core Values (2026) of Shanghai Haixin Group Co., Ltd.
Shanghai Haixin Group Co., Ltd. (600851.SS): Mission and Values
Shanghai Haixin Group Co., Ltd. (600851.SS) is a diversified conglomerate whose stated mission emphasizes 'innovation-driven, asset-light growth where possible, and steady capital returns to shareholders.' Core values highlighted by management include compliance, innovation in pharmaceuticals and textiles, prudent capital allocation, and long-term urban-industrial development. How it works - business model and operations- Corporate structure: operates through four principal divisions - pharmaceuticals, textiles & clothing, financial investments, and industrial park development - plus commodity trading and asset management arms.
- Revenue mix (illustrative FY figures): pharmaceuticals and textiles are primary operational revenues; financial investments and property/park leasing provide recurring income and capital gains.
- Capital allocation: uses listed equity, internal cash flows and occasional disposals of non-core assets to fund R&D, park construction and strategic equity stakes.
- Pharmaceuticals: R&D, manufacturing and distribution of medical products, with a strategic focus on oncology drugs and biologics; invests in clinical trials and GMP manufacturing upgrades.
- Textiles & clothing: production of artificial fur, plush toys and textile fabrics for domestic and export markets; integrates upstream raw-material sourcing with downstream OEM/ODM services.
- Financial investments: holds equity stakes in securities firms and fund managers; seats on boards enable influence over strategic and capital decisions, and the division realizes dividend income and trading gains.
- Industrial park development: develops and manages industrial property, offering build-to-suit and standard factory leases that generate stable rental income and service fees.
- Commodity trading & asset management: trading of raw materials and running asset-management vehicles to monetize group holdings and provide liquidity buffers.
| Metric | Amount (CNY, recent FY) |
|---|---|
| Revenue (total) | 1,230,000,000 |
| Net profit (attributable) | 60,000,000 |
| Total assets | 6,500,000,000 |
| Operating cash flow | 150,000,000 |
| Gross margin (group) | 28% |
| Return on equity (ROE) | 7.6% |
- Pharmaceuticals: 38% - sales of active pharmaceuticals, oncology-focused product lines and distribution fees.
- Textiles & clothing: 32% - artificial fur, plush goods and fabric sales, including export orders.
- Industrial park leasing & services: 16% - rental income, property management and development margins.
- Financial investments & trading: 14% - dividend income, investment gains and commodity trading profits.
- Pharmaceuticals: product sales, licensing, contract manufacturing, and milestone payments from collaborative R&D; higher margin on proprietary oncology formulations.
- Textiles & clothing: volume-based manufacturing margins, seasonal licensing for toy/character products, and B2B fabric sales to apparel brands.
- Financial investments: equity dividends, securities trading profits, asset-management fees, and board-level influence to protect capital returns.
- Industrial park development: upfront land and construction value appreciation, recurring lease revenue, property management fees and ancillary services (logistics, utilities).
- Commodity trading & asset management: short-term trading spreads, arbitrage, and fee income from managed funds or asset packages.
- Major shareholders: a mix of state-owned entities, institutional investors and founding shareholders; ownership stakes enable appointment of directors/supervisors to influence portfolio companies.
- Board & supervision: uses appointed directors in investee securities and fund companies to participate in strategic decisions and monitor compliance.
- Risk controls: hedging in commodity trading, portfolio diversification across cyclical and defensive businesses, and compliance with China's listed-company disclosure rules.
- R&D spend (pharmaceuticals): expressed as % of pharma revenue and absolute investments in clinical programs.
- Utilization rates for textile production lines and park occupancy rates (target >85% for stable cash flow).
- Investment portfolio returns and dividend yield from strategic equity holdings.
- Debt-to-asset and interest-coverage ratios to ensure financial flexibility for development projects.
Shanghai Haixin Group Co., Ltd. (600851.SS): How It Works
Shanghai Haixin Group Co., Ltd. (600851.SS) is a diversified conglomerate with core businesses spanning pharmaceuticals, textiles, financial investment, industrial park development, commodity trading and related services. The company combines manufacturing, investment holdings and property operations to generate cash flow and strategic returns across cyclical environments.- Founded and Listing: Established as a state-origin enterprise that transformed into a listed company; listed on the Shanghai Stock Exchange under ticker 600851.SS.
- Ownership: Controlled by a combination of state-related entities and institutional shareholders; key strategic stakes include holdings in securities firms, fund companies and industrial real estate operators.
- Mission & Vision: Focused on sustainable industrial development, healthcare product innovation and creating long-term value through diversified investments and asset management. See: Mission Statement, Vision, & Core Values (2026) of Shanghai Haixin Group Co., Ltd.
- Pharmaceuticals: Sale of chemical drugs, oncology treatments and related APIs (active pharmaceutical ingredients). This division supplies hospitals, distributors and export markets.
- Textile & Clothing: Production and sale of artificial fur, plush toys, textile fabrics and downstream garments - selling to domestic apparel makers and export channels.
- Financial Investment: Dividend and investment returns from equity stakes in securities companies and fund management firms; fees and performance income from the company's asset management platform.
- Industrial Park Development: Rental and property management income from leasing industrial premises, logistics and manufacturing space within Haixin-owned parks.
- Commodity Trading & Other Financial Services: Brokerage, trading margins, and short-term income from commodity trading, proprietary trading and related financial service arrangements.
- Diversification Strategy: Cross-sector exposure smooths profitability across economic cycles - industrial rents and investment income often offset volatility in pharma and textiles.
- Manufacturing & Sales: Vertical manufacturing in pharmaceuticals and textiles includes raw material sourcing, in-house production and wholesaling to medical distributors and apparel OEMs.
- Investment Platform: Haixin holds minority/strategic stakes in securities and fund houses that distribute management fees, commissions and dividends back to the group.
- Asset-Light vs Asset-Heavy Mix: Pharmaceuticals and textiles are asset- and capex-intensive; investment and asset management are asset-light and generate recurring fee income; industrial parks are capital-invested, rental-yield assets.
- Cash Recycling: Rental/operating cash and investment exits are recycled into new financial investments or capex for higher-margin pharma projects.
| Metric | Value | Notes |
|---|---|---|
| Total Revenue | ≈ RMB 3.6 billion | Consolidated revenue across all segments (latest reported year) |
| Net Profit | ≈ RMB 150-250 million | Net attributable profit to shareholders (subject to year-to-year volatility) |
| Pharma Revenue Share | ≈ 35-45% | Largest single segment by revenue |
| Textile & Clothing Revenue Share | ≈ 20-30% | Includes artificial fur, plush toys, fabrics |
| Financial Investment Income | ≈ 10-20% of operating income | Dividends, investment returns, asset management fees |
| Industrial Park Rental Income | ≈ 8-15% | Stable recurring rental cash flows |
| Total Assets | ≈ RMB 10-15 billion | Includes fixed assets, investment securities and property holdings |
| Debt / Equity Ratio | ≈ 0.6-1.0 | Moderate leverage reflecting property and manufacturing exposures |
- Segment diversification: Pharmaceuticals (higher margins, regulatory risk), Textiles (trade & commodity cyclical risk), Investments (market risk), Property (leasing & vacancy risk).
- Cross-subsidization: Investment returns and rental income provide buffers against manufacturing slowdowns and pharmaceutical product lifecycle risks.
- Capital allocation priorities: Reinvest in pharma R&D and manufacturing upgrades; selectively expand industrial park holdings; deploy liquid capital into securities/fund products when valuations are attractive.
| Source | Primary Cash Flow Type | Frequency |
|---|---|---|
| Pharmaceutical sales | Product revenue, gross margin | Ongoing (quarterly) |
| Textile & garment sales | Product revenue, seasonal order cycles | Ongoing (seasonal) |
| Investment holdings | Dividends, capital gains, fees | Periodic / opportunistic |
| Industrial park leasing | Rental income, service fees | Monthly / annual |
| Commodity trading & financial services | Trading profit, commissions | Short-term / transactional |
Shanghai Haixin Group Co., Ltd. (600851.SS): How It Makes Money
Shanghai Haixin Group Co., Ltd. (600851.SS) generates revenue through a diversified set of operations centered on medical and health services, industrial manufacturing, and related investments. Its portfolio approach reduces single-sector risk and enables cross-subsidization between higher-margin healthcare assets and stable industrial or service businesses.- Core healthcare operations: cancer treatment services, medical devices, and pharmaceuticals distribution.
- Industrial and manufacturing: production and sales of specialty materials and components used in healthcare equipment and other sectors.
- Investment and asset management: stakes in joint ventures, long-term financial investments, and rental/lease income from property holdings.
- Service revenue: technical services, maintenance contracts, and training programs for medical institutions.
| Metric | Value |
|---|---|
| Market Capitalization (late 2025) | CNY 5.99 billion |
| Trailing Twelve Months Revenue | CNY 788.05 million |
| Net Income (TTM) | CNY 156.25 million |
| Trailing P/E Ratio | 53.63 |
| Beta | 0.62 |
- Scale and valuation: A market cap of CNY 5.99 billion positions Shanghai Haixin as a small-to-mid cap company with room to scale through M&A or organic expansion in healthcare.
- Profitability mix: TTM revenue of CNY 788.05 million and net income of CNY 156.25 million imply operating margins supported by healthcare services and higher-margin product lines.
- Investor expectations: A trailing P/E of 53.63 reflects the market pricing in growth potential, particularly from oncology-related services and products.
- Risk profile: Low beta (0.62) indicates lower volatility versus broader Chinese equities, attractive to conservative investors seeking healthcare exposure.
- Growth catalysts: Demographic trends and national emphasis on healthcare-especially cancer diagnosis and treatment-support demand for the company's medical services and devices.
Shanghai Haixin Group Co., Ltd. (600851.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.